Antiviral combination therapies for persistent COVID-19 in immunocompromised patients
Description
After the third year of the COVID-19 pandemic, most of the severe COVID-19 burden falls upon immunocompromised patients who cannot mount endogenous immune response after both vaccination and/or natural infection. They also experience persistent SARS
